Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 1

Status

Completed 6

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Myeloid 6

Conditions

Polycythemia Vera 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Thrombocythemia, Essential 5Philadelphia Chromosome 2Myeloproliferative Disorders 2Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Melanoma 1Leukemia 1Carcinoma, Renal Cell 1Blast Crisis 1

Interventions

fludarabine phosphate 29ruxolitinib 28Peripheral Blood Stem Cell Transplantation 26Cyclophosphamide 25Busulfan 21Tacrolimus 16Whole-Body Irradiation 15Mycophenolic Acid 14Methotrexate 13Cyclosporine 12Hydroxyurea 11Antilymphocyte Serum 11Aspirin 9fludarabine 8Filgrastim 8Melphalan 7Etoposide 7Decitabine 7peginterferon alfa-2a 6Imatinib Mesylate 6Cytarabine 611-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6givinostat hydrochloride 5givinostat 5Radiotherapy 5Prednisone 5Carboplatin 5Biopsy 5Topotecan 4Thiotepa 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Polycythemia Vera × peginterferon alfa-2a × Myeloid × Clear all
NCT00452023 2024-12-11

Pegasys® in Patients With Myeloproliferative Diseases

M.D. Anderson Cancer Center

Phase 2 Completed
83 enrolled 12 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential

NCT01387763 2022-04-27

DALIAH

Odense University Hospital

Phase 3 Completed
202 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT02407080 2019-09-12

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT01259856 2019-04-30

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Icahn School of Medicine at Mount Sinai

Phase 3 Completed
168 enrolled 16 charts
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT01259817 2017-01-11

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

Icahn School of Medicine at Mount Sinai

Phase 2 Completed
135 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT00241241 2015-10-21

Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera

PV-Nord

Phase 2 Completed
40 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡